Why, Who, When, Where and More: New Draft Guidance on Notifying FDA about Discontinuance or Interruption in Manufacturing
FDA Law Blog
MARCH 4, 2024
blood supply; and, Manufacturers of certain finished drug products marketed without an approved NDA or ANDA. Others involved in the drug supply chain, such as third-party API manufacturers and suppliers, are not required to submit such notifications.
59 
Let's personalize your content